Pulsed field ablation (PFA) represents a tissue-selective ablation modality using irreversible electroporation to target myocardial sleeves while sparing adjacent structures such as esophagus and phrenic nerve, potentially improving safety over thermal radiofrequency ablation for paroxysmal atrial fibrillation. 
The BEAT PAROX-AF trial conducted across nine European centers prospectively randomized symptomatic patients aged 18 to 80 years with drug-refractory paroxysmal atrial fibrillation one-to-one to pentaspline pulsed field ablation or point-by-point radiofrequency ablation (RFA) guided by the CLOSE protocol incorporating contact force sensing catheters and electroanatomical mapping. The trial results were published in the European Heart Journal. 
The primary endpoint assessed single-procedure efficacy defined as freedom from atrial arrhythmia recurrence lasting 30 seconds or longer, cardioversion, class I/III antiarrhythmic drug reinstitution, or repeat ablation following a two-month blanking period at 12 months. Investigators captured procedure-related serious adverse events and individual endpoint components through January 2024 enrollment.
Comparable Single-Procedure Durability
Of 292 randomized patients, 289 underwent analysis with median age 63.5 years and 58% male distribution. Single-procedure success reached 77.2% in 145 pulsed field ablation patients versus 77.6% in 144 radiofrequency patients, yielding an adjusted difference of 0.9% with 95% confidence interval -8.2% to 10.1% and P-value of 0.84. This equivalence held across prespecified subgroups without evidence of treatment interaction.
Safety Profile Favors Pulsed Field Approach
Serious procedure-related adverse events proved less frequent with pulsed field ablation at 3.4% versus 7.6% for radiofrequency ablation, corresponding to a -3.3% difference with 95% confidence interval -8.4% to 1.8%. No deaths, persistent phrenic nerve palsy, or strokes occurred in either arm. Radiofrequency complications included two pulmonary vein stenoses exceeding 70%, 12 greater than 50%, two cardiac tamponades, and one esophageal bleed, underscoring thermal injury risks.
Clinical Implications for AF Ablation Practice
Electrophysiologists treating paroxysmal atrial fibrillation gain randomized evidence affirming pulsed field ablation noninferiority to optimized point-by-point radiofrequency using contemporary CLOSE guidance, with a more favorable safety margin. The pentaspline system's single-shot delivery streamlines procedural efficiency while mitigating esophageal and phrenic nerve injury prevalent in thermal ablation. These findings support broader pulsed field adoption as first-line therapy in eligible paroxysmal cohorts, pending longer-term durability data.